I-Mab (IMAB)
NASDAQ: IMAB · Real-Time Price · USD
4.630
-0.010 (-0.22%)
At close: Oct 29, 2025, 4:00 PM EDT
4.720
+0.090 (1.94%)
After-hours: Oct 29, 2025, 7:59 PM EDT
I-Mab Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
533.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 632.00K | 2.18M | -140.75% |
| Dec 31, 2022 | -1.55M | -15.41M | -111.19% |
| Dec 31, 2021 | 13.86M | -222.44M | -94.14% |
| Dec 31, 2020 | 236.29M | 231.99M | 5,384.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IMAB News
- 14 hours ago - I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform - GlobeNewsWire
- 7 days ago - I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 - GlobeNewsWire
- 12 days ago - I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript - Seeking Alpha
- 13 days ago - I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences - GlobeNewsWire
- 15 days ago - I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference - GlobeNewsWire
- 7 weeks ago - I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market - Seeking Alpha
- 2 months ago - I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee - GlobeNewsWire
- 2 months ago - I-Mab to Participate in September Investor Conferences - GlobeNewsWire